For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.
An article from
Dive Brief
//
Obesity drugs
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.
Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset
Hanmi Pharm signs $2.3 bil. licensing deal with Roche's Genentech for obesity drug candidate - The Korea Times
Roche snags rights to South Korean obesity treatment
Hanmi signs record $2.3b obesity drug deal with Genentech
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
Hanmi dispara 30% após acordo de US$ 2,31 bi com subsidiária da Roche para tratamento de obesidade
Hanmi Pharm in spotlight as Korea's 1st obesity drug nears launch - The Korea Times
Roche earmarks $750M to double the size of its Oregon manufacturing facility
Roche licenses Hanmi Pharm's non-incretin obesity drug HM17321 in a deal worth up to $2.3B, including $190M upfront.
Hanmi Pharm, a Korean pharmaceutical company, said Monday it has signed a 3.2 trillion-won ($2.3 billion) licensing deal with…
Roche subsidiary secures global rights to manufacture South Korean obesity treatment.
Swiss pharmaceutical firm Roche is investing billions in new obesity treatments in hopes of breaking into a highly competitive…
Hanmi Pharmaceutical said Monday it has inked an exclusive licensing agreement with Genentech for its obesity drug candidate…
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
